

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added  
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 8 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 9 FEB 11 WTEXTILES reloaded and enhanced  
NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS  
patent records provide insights into related prior  
art  
NEWS 11 FEB 19 Increase the precision of your patent queries -- use  
terms from the IPC Thesaurus, Version 2009.01  
NEWS 12 FEB 23 Several formats for image display and print options  
discontinued in USPATFULL and USPAT2  
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields  
and 2009 MeSH terms  
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more  
precise author group fields and 2009 MeSH terms  
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into  
STN patent clusters  
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status  
display data from INPADOCDB  
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display  
formats  
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text  
applications and grants  
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced  
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role  
for nanomaterial substances  
NEWS 21 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent  
equivalents from China  
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced  
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances  
enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:31:27 ON 06 APR 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:31:36 ON 06 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:	5 APR 2009	HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:	5 APR 2009	HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10564139s1.str



```

chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
6-7 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19
15-16 16-17 16-20 17-18 17-22 18-19 20-21 21-22
exact/norm bonds :
6-7 7-8 7-12 8-9 9-10 10-11 10-13 11-12 16-20 17-22 20-21 21-22
exact bonds :
13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom


```

L1 STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1 STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:31:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```

BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 671 TO 1569  
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA \$\$\$ SAM L1

=> s l1 \$\$\$ full  
FULL SEARCH INITIATED 12:32:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1306 TO ITERATE

100.0% PROCESSED 1306 ITERATIONS 301 ANSWERS  
SEARCH TIME: 00.00.01

L3 301 SEA \$\$\$ FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 12:32:06 ON 06 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15  
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3  
L4 482 L3  
=> s l3 and cyclodextrin  
482 L3  
39726 CYCLODEXTRIN  
11071 CYCLODEXTRINS  
40770 CYCLODEXTRIN  
(CYCLODEXTRIN OR CYCLODEXTRINS)  
L5 6 L3 AND CYCLODEXTRIN

=> d ibib abs hitstr 1-6

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1359892 CAPLUS

DOCUMENT NUMBER: 149:519140

TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders

INVENTOR(S): Braun, Marina; Schollmayer, Erwin; Sachse, Richard

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 58pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

# PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008135527	A2	20081113	WO 2008-EP55413	20080502
WO 2008135527	A3	20090212		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1987815	A1	20081105	EP 2007-9013	20070504
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504  
US 2007-915964P P 20070504


AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5

g/l,  $\alpha$ -cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1324859 CAPLUS

DOCUMENT NUMBER: 149:500102

TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: Eur. Pat. Appl., 33pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1987815	A1	20081105	EP 2007-9013	20070504
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080274061	A1	20081106	US 2008-114348	20080502
WO 2008135527	A2	20081113	WO 2008-EP55413	20080502
WO 2008135527	A3	20090212		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504  
US 2007-915964P P 20070504


AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5

g/l,  $\alpha$ -cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:645606 CAPLUS

DOCUMENT NUMBER: 145:460196

TITLE: Enhancement in dissolution pattern of piribedil by molecular encapsulation with  $\beta$ -cyclodextrin

AUTHOR(S): Demirel, M.; Buyukkoroglu, G.; Kalava, B. S.; Yazan, Y.

CORPORATE SOURCE: Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir, Turk.

SOURCE: Methods and Findings in Experimental and Clinical Pharmacology (2006), 28(2), 83-88  
CODEN: MFEFDX; ISSN: 0379-0355

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to improve the dissoln. behavior of piribedil by mol. encapsulation with  $\beta$ -cyclodextrin ( $\beta$ -CD). Toward this aim, phys. mixing, co-grinding, and spray-drying methods were used to prepare solid binary systems. Differential scanning calorimetry, X-ray diffractometry, and particle size anal. were used to characterize the binary systems obtained. Complexes of piribedil and  $\beta$ -CD could be prepared using the spray-drying method. Dissoln. of piribedil was improved to a great extent by the complex prepared


IT 3605-01-4, Piribedil

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(mol. encapsulation of piribedil with  $\beta$ -cyclodextrin using spray-drying method showed enhanced dissoln. pattern)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 2005:56829 CAPLUS

DOCUMENT NUMBER: 142:141273

TITLE: Pharmaceutical composition for the nasal administration of piribedil  
 INVENTOR(S): Rolland, Herve; Wuthrich, Patrick  
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.; Servier Lab  
 SOURCE: Fr. Demande, 9 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2857594	A1	20050121	FR 2003-8712	20030717
FR 2857594	B1	20050916		
AU 2004258714	A1	20050203	AU 2004-258714	20040716
CA 2532631	A1	20050203	CA 2004-2532631	20040716
WO 2005009442	A1	20050203	WO 2004-FR1867	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1653963	A1	20060510	EP 2004-767691	20040716
EP 1653963	B1	20061227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR CN 1819828 A 20060816 CN 2004-80019749 20040716 BR 2004012681 A 20061003 BR 2004-12681 20040716 AT 349213 T 20070115 AT 2004-767691 20040716 JP 2007516947 T 20070628 JP 2006-519966 20040716 ES 2279435 T3 20070816 ES 2004-767691 20040716 NZ 544460 A 20080430 NZ 2004-544460 20040716 IN 2006DN00118 A 20070824 IN 2006-DN118 20060106 US 20060204449 A1 20060914 US 2006-564139 20060110 MX 2006000641 A 20060330 MX 2006-641 20060117 KR 2006031689 A 20060412 KR 2006-701141 20060117 KR 807480 B1 20080225 NO 2006000743 A 20060216 NO 2006-743 20060216 FR 2003-8712 A 20030717 WO 2004-FR1867 W 20040716				
PRIORITY APPLN. INFO.:				
AB The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin) 750, and NaCl 68 mg, and water qs to 10 mL. IT 3605-01-4, Piribedil RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical composition for nasal administration of piribedil) RN 3605-01-4 CAPLUS CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)				





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:988974 CAPLUS

DOCUMENT NUMBER: 124:66420

ORIGINAL REFERENCE NO.: 124:12273a,12276a

TITLE: Effects of  $\beta$ - cyclodextrins on skin: implications for the transdermal delivery of piriabedil and a novel cognition enhancing-drug, S-9977

AUTHOR(S): Legendre, J. Y.; Rault, I.; Petit, A.; Luijten, W.; Demuyne, I.; Horvath, S.; Ginot, Y. M.; Cuine, A. Ardix, Rue Eugene Vignat, Orleans, 45000, Fr.

CORPORATE SOURCE: European Journal of Pharmaceutical Sciences (1995), 3(6), 311-22

SOURCE: CODEN: EPSCED; ISSN: 0928-0987

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The effects of  $\beta$ - cyclodextrin ( $\beta$ -CD), randomly methylated  $\beta$ - cyclodextrin (RAMEB) and 2-hydroxypropyl  $\beta$ - cyclodextrin (HP $\beta$ -CD) on skin were investigated. The three cyclodextrins (CDs) were able to destabilize model liposomes and to extract significant amts. of cholesterol from isolated stratum corneum (SC). However, only RAMEB extracted all the major lipid classes from isolated SC, as shown by thin layer chromatog. Both RAMEB and HP $\beta$ -CD could release 5-10% of the extractable cholesterol as well as proteins from hairless rat skin. Nevertheless, CDs did not induce any major modification of the differential scanning calorimetry (DSC) profile or the Fourier-transformed IR (FTIR) spectrum of SC. This was explained by the low percutaneous penetration of CDs. Furthermore, the influence of RAMEB on the transdermal diffusion through hairless rat skin of piriabedil, a central dopaminergic agonist and of S-9977, a novel cognition enhancing drug, was studied. RAMEB was found to decrease the transdermal flux of piriabedil, with which it forms an inclusion complex, as shown by NMR. Conversely, RAMEB increased by 2-fold the percutaneous absorption of the S-9977 hydrochloride, which does not interact with CD. Finally, a combination of oleic acid and RAMEB greatly increased by about 30-fold the flux of S-9977 hydrochloride.

IT 3605-01-4, Piriabedil  
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (effects of  $\beta$ - cyclodextrins on skin: implications for the transdermal delivery of piriabedil and a novel cognition enhancing-drug, S-9977)


RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:726272 CAPLUS  
 DOCUMENT NUMBER: 123:123180  
 ORIGINAL REFERENCE NO.: 123:21721a,21724a  
 TITLE: Pharmaceutical compositions containing partially  
 methylated  $\beta$ -cyclodextrines as absorption  
 promoters  
 INVENTOR(S): Cuine, Alain; De Jong, Hendrik J.  
 PATENT ASSIGNEE(S): Adir et Cie., Fr.  
 SOURCE: Can. Pat. Appl., 9 pp.  
 CODEN: CPXXEB  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2132511	A1	19950323	CA 1994-2132511	19940920
FR 2710268	A1	19950331	FR 1993-11258	19930922
FR 2710268	B1	19951020		
EP 649653	A1	19950426	EP 1994-402061	19940915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9474111	A	19950406	AU 1994-74111	19940920
JP 07247223	A	19950926	JP 1994-226875	19940921
ZA 9407401	A	19950515	ZA 1994-7401	19940922
PRIORITY APPLN. INFO.:			FR 1993-11258	A 19930922
AB	Partially methylated $\beta$ -cyclodextrines are used as absorption promoters in transdermal pharmaceutical compns. A pharmaceutical lotion contained estradiol (I) 5, dimethyl- $\beta$ - cyclodextrin (II) 48.875 g, NaOH solution q.s. pH = 7.4, and water q.s. 1000mL. The flux of I in hairless rat skin was 2.4 as compared with 1.2 $\mu\text{g}/\text{cm}^2/\text{h}$ for controls having no II.			
IT	3605-01-4, Piribedil RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. containing partially methylated $\beta$ -cyclodextrines as absorption promoters)			
RN	3605-01-4 CAPLUS			
CN	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)			



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
41.08	227.18

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.92	-4.92

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:37:55 ON 06 APR 2009